Last reviewed · How we verify
Intravenous thrombolysis agents
Intravenous thrombolysis agents dissolve blood clots by converting plasminogen to plasmin, which breaks down fibrin and restores blood flow in occluded vessels.
Intravenous thrombolysis agents dissolve blood clots by converting plasminogen to plasmin, which breaks down fibrin and restores blood flow in occluded vessels. Used for Acute ischemic stroke, Acute myocardial infarction, Pulmonary embolism.
At a glance
| Generic name | Intravenous thrombolysis agents |
|---|---|
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Drug class | Thrombolytic agent / Fibrinolytic agent |
| Target | Plasminogen / Fibrin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
These agents work by activating the fibrinolytic cascade, converting the inactive zymogen plasminogen into its active form, plasmin. Plasmin then degrades fibrin cross-links that form the structural basis of blood clots, thereby dissolving thrombi and restoring perfusion to ischemic tissue. Common agents in this class include tissue plasminogen activator (tPA), streptokinase, and urokinase.
Approved indications
- Acute ischemic stroke
- Acute myocardial infarction
- Pulmonary embolism
- Deep vein thrombosis
Common side effects
- Bleeding (intracranial hemorrhage)
- Systemic bleeding
- Reperfusion arrhythmias
- Hypotension
- Allergic reaction
Key clinical trials
- Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window (PHASE4)
- Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT) (PHASE4)
- Early Endovascular Treatment in Isolated Internal Carotid Artery Occlusion (NA)
- Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits (PHASE4)
- Intravenous Thrombolysis in Acute Ischemic Stroke with Active Cancer (PHASE3)
- Intravenous Thrombosis and Patients with Prior Ischemic Stroke Within 3 Months (PHASE3)
- A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion (PHASE3)
- ACT-GLOBAL Adaptive Platform Trial for Stroke (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: